Deborah Lotterman discusses the challenges translating medical science into communications in STAT News:
Precision for Value’s Jeremy Schafer discusses managing biosimilars and the implications for health systems in a new article for Biosimilars Development.
Precision subject matter expert Pat Devitt examines the 3 advances driving oncology clinical trial success in a special editorial for STAT News.
Precision Health Economics’ Senior Research Economist Jason Shafrin provides an in-depth analysis of value frameworks in a new article for Pharmaceutical Commerce.
Precision Health Economics’ Dana Goldman addresses the firestorm created by Mylan’s dramatic price hikes for their EpiPen in a new commentary published in STAT News: “To Prevent Another EpiPen Controversy, the Government Should Step In.”
Precision Health Economics’ Dana Goldman offers his latest opinion piece for the New York Times,”Hospital Care for Those Who Can Afford It Helps Care for Those Who Can’t.” In his commentary, Dr. Goldman suggests that concierge care may paradoxically be the best hope for ensuring continued access to healthcare for the indigent uninsured.
In the latest edition of Life Science Leader, Precision’s Andre Pinheiro, Mansi Vithlani, Kyle Sarnataro, and Alex Grosvenor examine the introduction of Anti-TNF Biosimilars in Europe.
In his latest Forbes.com commentary, Precision Health Economics co-founder Tomas Philipson (along with Precision co-author Jason Shafrin) addresses the development of new value frameworks, and how both physicians and patients are at risk.
Rick Lifsitz and Larry Blandford address market access for novel Alzheimer’s treatments in a new commentary for Journal of Clinical Pathways
Precision’s Chandra and Shafrin Address Value Frameworks in JAMA